Octagon Capital Advisors LP
Source: SEC Form 13F · as of Mar 2026Octagon Capital Advisors LP holds 15 biotech & pharma companies tracked by BioSniper, totaling $627.4M in value as of Mar 2026 (SEC Form 13F).
Companies held
15
Total value held
$627.4M
BioSniper AIPage evidence connected
Prepared research question
What matters most for Dianthus Therapeutics, Inc. /DE/ (DNTH)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| DNTHDianthus Therapeutics, Inc. /DE/ | 1,946,667 | $163.4M |
| COGTCogent Biosciences, Inc. | 2,350,000 | $90.5M |
| ABVXAbivax SA | 677,000 | $75.4M |
| ALMSALUMIS INC. | 2,830,700 | $62.4M |
| DFTXDefinium Therapeutics Inc. | 2,440,000 | $46.1M |
| BIOABioAge Labs, Inc. | 1,748,000 | $30.6M |
| CNTACentessa Pharmaceuticals plc | 750,000 | $29.8M |
| KALVKalVista Pharmaceuticals, Inc. | 1,450,000 | $29.2M |
| TERNTerns Pharmaceuticals, Inc. | 530,000 | $27.9M |
| OCULOCULAR THERAPEUTIX, INC | 3,166,600 | $26.8M |
| IRONDisc Medicine, Inc. | 270,000 | $17.3M |
| CNTXContext Therapeutics Inc. | 5,250,000 | $13.8M |
| BBOTBridgeBio Oncology Therapeutics, Inc. | 719,000 | $6.4M |
| PHVSPharvaris N.V. | 165,000 | $4.7M |
| CATXPerspective Therapeutics, Inc. | 791,555 | $3.3M |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.